Start here if you're new
what it is
It is trying to sell an eye drug for wet macular degeneration in Europe and the US.
how it gets paid
Last year Outlook Therapeutics made $1M in revenue. Germany was the main engine at $0.4M, or 40% of sales.
what just happened
Revenue was $2M last quarter, while EPS came in at -$0.38.
At a glance
C+ balance sheet — struggling to keep the lights on
15/100 earnings predictability — expect surprises
-$4.06 fy2024 eps est
-$5010M fy2024 rev est
n/a operating margin
xvary composite: 28/100 — weak
What they do
It is trying to sell an eye drug for wet macular degeneration in Europe and the US.
The edge is regulatory, not magical. LYTENAVA already has 2 approvals, from the European Commission and the UK regulator, while the US is still waiting on a December 31, 2025 FDA decision. That is 2 green lights versus 1 pending filing, and you are buying a 23-person company in the middle of that gap.
How they make money
$1M
annual revenue
Germany
$0.4M
United Kingdom
$0.3M
United States
$0.2M
Other Europe
$0.1M
The products that matter
wet AMD treatment candidate
LYTENAVA™ (ONS-5010)
$1M · 100% of shown revenue
This is the entire commercial story right now. It produced 100% of the $1M in revenue shown in this snapshot. If this asset gets through the FDA and finds adoption, the company has a path. If it stalls, there is no second engine waiting offstage.
single asset
Key numbers
-$4.06
fy2024 eps est
-$5010M
fy2024 rev est
82.2%
gross margin
Gross profit kept about -82.2% of each revenue dollar.
n/a
dividend yield
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $21M (39% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for OTLK right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue was $2M last quarter, while EPS came in at -$0.38.
The company is still running a tiny top line against big development costs. The -82.2% gross margin says the sales base is not covering direct costs yet.
$2.0M
revenue
-$0.38
eps
82.2%
gross margin
the number that mattered
The -82.2% gross margin mattered most. It says the company loses money before overhead even enters the room.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
OTLK's risk list is unusually concentrated because the company is unusually concentrated. One FDA path, one product, $8.7M of cash, and a market cap around $33M leave you very little room for a soft landing.
med
The regulatory thesis can still break
The March 2026 Type A meeting shows the filing is still alive, but a live filing is not the same thing as approval. If the FDA asks for more work or rejects the route again, the main asset loses time and the equity usually pays for it.
With one drug candidate driving 100% of the revenue shown here, there is no internal backup plan if the path slips again.
med
Cash burn can still turn into dilution
The company had $8.7M in cash in the latest quarter and $21M of long-term debt, including an $18.4M note now extended to December 2026. That's enough to keep the story alive. It is not enough to make financing risk disappear.
A new capital raise would hit a company worth roughly $33M, so even a modest financing can matter a lot to your ownership stake.
med
Approval would only start the hard part
Wet AMD is not an empty market waiting for OTLK to arrive. Initial sales of $1M prove a launch exists. They do not prove doctors, payers, or distribution will support scale.
You could get a regulatory win and still end up owning a company with weak adoption, ugly margins, and another financing need.
With $8.7M of cash, $21M of long-term debt, and one product responsible for 100% of the $1M revenue shown here, the bear case does not need a dramatic scandal. It just needs time, delay, or weak uptake.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next FDA milestone
The stock does not need a beautiful quarter. It needs a clearer regulatory path than you have today.
metric
cash versus the current $8.7M base
If cash keeps sliding while losses stay heavy, financing stops being a possibility and becomes the main event.
risk
any new equity or debt terms
A company worth roughly $33M does not have much room for painless financing. The terms matter as much as the amount.
trend
whether sales move beyond the current $1M start
The first $1M proves there is a launch. The next step is proving the launch can become a business before cash pressure returns.
Analyst rankings
earnings predictability
15 / 100
in human-speak, analysts do not have a stable operating model to work with yet because one asset still drives nearly every meaningful assumption.
risk rank
5
Safer than just 5% of stocks in the dataset. That's the market's way of telling you this name trades on company-specific events, not calm compounding.
source: institutional data
Institutional activity
institutional ownership data for OTLK is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive